ReviewJournal of clinical medicine2020
Bone Regeneration, Reconstruction and Use of Osteogenic Cells; from Basic Knowledge, Animal Models to Clinical Trials.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 86 citations in OpenAlex.
- A rapidly fabricated bone marrow enrichment material with a controllable pore size promotes osteogenesis close to autogenous bone graft in clinic.Journal of advanced research · 2026Article
- Magnetic nanoparticle formulations to activate TREK and Piezo mechanosensitive ion channels (MICA) for enhanced osteogenesis.Regenerative biomaterials · 2026Article
- The Future of Dental Implants: A Narrative Review of Trends, Technologies, and Patient Considerations.Cureus · 2025Review
- Biomaterials for Guided Tissue Regeneration and Guided Bone Regeneration: A Review.Dentistry journal · 2025Review
- Innovation in Osteogenesis Activation: Role of Marine-Derived Materials in Bone Regeneration.Current issues in molecular biology · 2025Review
- Integrating Micro- and Nanostructured Platforms and Biological Drugs to Enhance Biomaterial-Based Bone Regeneration Strategies.Biomacromolecules · 2025Review
- Emerging Strategies for Bioactive Agent-Loaded Xenogeneic Bone Scaffolds in Regenerative Medicine: A Comprehensive Review.Drug design, development and therapy · 2025Review
- Strategies for Craniofacial Tissue Engineering: Innovations for Scalable Bone Regeneration.Plastic and aesthetic research · 2025Article
- Controlled delivery of mesenchymal stem cells via biodegradable scaffolds for fracture healing.Nanomedicine (London, England) · 2025Review
- Translation of cell therapies to treat autoimmune disorders.Advanced drug delivery reviews · 2024Review
- Impact of 17β-Estradiol on the Shape, Survival, Osteogenic Transformation, and mRNA Expression of Gingiva-Derived Stem Cell Spheroids.Medicina (Kaunas, Lithuania) · 2023Article
- Remote Activation of Mechanotransduction via Integrin Alpha-5 via Aptamer-Conjugated Magnetic Nanoparticles Promotes Osteogenesis.Pharmaceutics · 2023Article
- Dual-Crosslinking of Gelatin-Based Hydrogels: Promising Compositions for a 3D Printed Organotypic Bone Model.Bioengineering (Basel, Switzerland) · 2023Article
- Regenerative engineering of long bones using the small molecule forskolin.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Vascularization of a Bone Organoid Using Dental Pulp Stem Cells.Stem cells international · 2023Article
- The Roles ofGenes · 2022Review
- Review
- A ComparativeFrontiers in cell and developmental biology · 2022Article
- Effect of microtopography on osseointegration of implantable biomaterials and its modification strategies.Frontiers in bioengineering and biotechnology · 2022Review
- Current applications of adipose-derived mesenchymal stem cells in bone repair and regeneration: A review of cell experiments, animal models, and clinical trials.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The deterioration of the human skeleton's capacity for self-renewal occurs naturally with age. Osteoporosis affects millions worldwide, with current treatments including pharmaceutical agents that target bone formation and/or resorption. Nevertheless, these clinical approaches often result in long-term side effects, with better alternatives being constantly researched. Mesenchymal stem cells (MSCs) derived from bone marrow and adipose tissue are known to hold therapeutic value for the treatment of a variety of bone diseases. The following review summarizes the latest studies and clinical trials related to the use of MSCs, both individually and combined with other methods, in the treatment of a variety of conditions related to skeletal health. For example, some of the most recent works noted the advantage of bone grafts based on biomimetic scaffolds combined with MSC and growth factor delivery, with a greatly increased regeneration rate and minimized side effects for patients. This review also highlights the continuing research into the mechanisms underlying bone homeostasis, including the key transcription factors and signalling pathways responsible for regulating the differentiation of osteoblast lineage. Paracrine factors and specific miRNAs are also believed to play a part in MSC differentiation. Furthering the understanding of the specific mechanisms of cellular signalling in skeletal remodelling is key to incorporating new and effective treatment methods for bone disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.